Mark H. Katz, MD

Clinical Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

I have a special interest and fellowship training in urological oncology. In particular, my clinical interests include prostate, bladder, kidney, and testicular cancer.

Publications

  • Published 6/4/2024

    Labban M, Stone BV, Steele GL, Salinas KE, Agudile E, Katz MH, Rihan-Porter N, Reich AJ, Cole AP, Landers S, Trinh QD. A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts. Cancer. 2024 Oct 15; 130 Suppl 20:3590-3601. PMID: 38837334.

    Read at: PubMed

  • Published 4/11/2022

    Mori JO, Shafran JS, Stojanova M, Katz MH, Gignac GA, Wisco JJ, Heaphy CM, Denis GV. Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins. Prostate. 2022 Jun; 82(10):1005-1015. PMID: 35403746.

    Read at: PubMed

  • Published 3/9/2021

    Ionson A, Monfared SHB, Ursiny M, Katz M, Wang D, Babayan R, Wason S. Economic Evaluation of 1470?nm Diode Laser Enucleation vs Bipolar Transurethral Resection of the Prostate. J Endourol. 2021 08; 35(8):1204-1210. PMID: 33499745.

    Read at: PubMed

  • Published 1/5/2021

    Carpinito G, Shepherd S, Wang DS, Katz MH, Wason SEL. Reply by Authors. Urol Pract. 2021 Mar; 8(2):283. PMID: 37145649.

    Read at: PubMed

  • Published 12/1/2020

    Poulson MR, Helrich SA, Kenzik KM, Dechert TA, Sachs TE, Katz MH. The impact of racial residential segregation on prostate cancer diagnosis and treatment. BJU Int. 2021 06; 127(6):636-644. PMID: 33166036.

    Read at: PubMed

Other Positions

  • Member, BU-BMC Cancer Center
    Boston University
  • Member, Amyloidosis Center
    Boston University

Education

  • Boston University School of Medicine, MD
  • University of Michigan at Ann Arbor, BS